TG Therapeutics | TGTX - Equity Capital And Reserves


TG Therapeutics reported $604.08M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Amgen USD 11.69B 2.5B Jun/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
Bayer EUR 29.71B 863M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Corcept Therapeutics USD 705.78M 67.79M Jun/2026
Curis USD 12.71M 7.24M Mar/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Novavax USD -190.71M 45.94M Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
TG Therapeutics USD 604.08M 20.95M Jun/2026
Verastem USD 81.78M 24.58M Mar/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026